PLEC

Across TCGA pan-cancer cohorts, PLEC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLEC data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLEC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLEC expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PLEC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.823	1.000	.008	20	view →
PDAC	DFS	Tertile	All	0.295	0.537	.016	12	view →
GBM	DFS	Tertile	All	0.237	0.511	.004	11	view →
UCEC	OS	Median	All	0.981	0.917	.041	2	view →
LSCC	OS	Quartile	All	0.735	0.939	.033	2	view →
LUAD	OS	Median	II,III,IV	0.508	0.798	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLEC–CCRCC (OS)

Open the CCRCC breakdown →